FDA Authorizes Pfizer's Paxlovid Pill for Covid-19
By Kathryn Hardison
The Food and Drug Administration on Wednesday authorized
pharmacists to prescribe Pfizer Inc.'s antiviral Paxlovid pill to
eligible patients, with some limitations, for the treatment of
Paxlovid is authorized for adults and pediatric patients with
mild-to-moderate cases who are at high risk for progression to
severe Covid-19, including hospitalization or death. It must be
taken within five days after symptoms begin, the FDA said.
Pharmacists should refer patients for clinical evaluations if
they don't have enough information available related to potential
drug interactions or to asses renal and hepatic functions, among
Patrizia Cavazzoni, director for the FDA's Center for Drug
Evaluation and Research, said in a statement that "authorizing
state-licensed pharmacists to prescribe Paxlovid could expand
access to timely treatment for some patients who are eligible to
receive this drug for the treatment of COVID-19."
Pfizer requested full FDA approval last week. Pfizer has been
selling the drug to the federal government under an authorization
for emergency use. The federal government has then been directing
the pills' distribution.
Write to Kathryn Hardison at email@example.com
(END) Dow Jones Newswires
July 06, 2022 13:56 ET (17:56 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
から 9 2023 まで 10 2023
から 10 2022 まで 10 2023